A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to AG-1749 (30mg Once-Daily) in Patients With Erosive Esophagitis
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to AG-1749 (30mg Once-Daily) in Patients With Erosive Esophagitis
The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.
Inclusion Criteria:
Exclusion Criteria:
Abiko-shi, Chiba, Japan
Itoshima-shi, Fukuoka, Japan
Kurume-shi, Fukuoka, Japan
Onga-gun, Fukuoka, Japan
Annaka-shi, Gunma, Japan
Aki-gun, Hiroshima, Japan
Amagasaki-shi, Hyōgo, Japan
Takarazuka-shi, Hyōgo, Japan
Sakade-shi, Kagawa-ken, Japan
Susaki-shi, Kochi, Japan
Fuziidera-shi, Osaka, Japan
Otawara-shi, Tochigi, Japan
Chiyoda-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Nakano-ku, Tokyo, Japan
Setagaya-ku, Tokyo, Japan